Radiopharm Theranostics : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)

About this update from Radiopharm Theranostics Limited

This Amendment No. 1 to Form 20-F (the "Amendment") amends our annual report on Form 20-F for the year ended June 30, 2025 (the "Annual Report"), which was originally filed with the U.S. Securities and Exchange Commission on September 18, 2025. The purpose of this Amendment is (i) to amend Item 4 - B. Business Overview - Intellectual Property and Patent Portfolio by replacing such sections with the information presented below and (ii) to amend Item 6 - C. Board Practices by adding the information presented below. This Amendment does not reflect events occurring after the filing of the Annual Report and does not modify or update the disclosure therein in any way except as described above or herein. No other changes have been made to the Annual Report. The filing of this Amendment should not be understood to mean that any statements contained in the Annual Report, as amended by this Amendment, are true or complete as of any date subsequent to the original filing date of the Annual Report. Accordingly, this Amendment should be read in conjunction with the Annual Report. As required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended, the Company is also filing or furnishing the certifications required under Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 as exhibits to this Amendment. Except for the matters described above, this Amendment does not modify or update any other disclosures in, or exhibits to, the Annual Report, and does not reflect any events occurring after the date of the Annual Report.

View stock analysis, news, and events for Radiopharm Theranostics Limited